2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal Of The National Cancer Institute 2020, 113: 808-819. PMID: 33369635, PMCID: PMC8487652, DOI: 10.1093/jnci/djaa201.Peer-Reviewed Original ResearchConceptsBreast cancerClinical utilityKi67 immunohistochemistryInternational Ki67Breast Cancer Working GroupAnalytical validityAssessment of Ki67HER2-negative patientsBreast cancer careCancer Working GroupGroup consensus meetingAdjuvant chemotherapyVisual scoring methodPatient groupCancer careT1-2Prognostic markerPrognosis assessmentPrognosis estimationTreatment decisionsEstrogen receptorHER2 testingConsensus meetingCurrent evidenceClinical validity
2019
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V. Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. Npj Breast Cancer 2019, 5: 28. PMID: 31482108, PMCID: PMC6715641, DOI: 10.1038/s41523-019-0122-x.Peer-Reviewed Original ResearchBreast cancerQuantitative immunofluorescenceIHC 0/1Systemic treatmentRT-qPCRClinical Oncology/CollegeAdditional outcome informationProtein expressionReal-time quantitative reverse transcription polymerase chain reactionHER2 protein levelsQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionASCO/CAP recommendationsRNA/protein expressionQIF scoresPatient characteristicsClinical outcomesTrastuzumab treatmentSurvival outcomesPolymerase chain reactionIHC 2Treatment decisionsCAP recommendationsPatients